StockWatch
·

PANACEA BIOTEC LTD. Q2 FY27 Results

PANACEABIOQ2 FY27 Results
Filing
Result:Good· Market: Up#Turnaround#Margin expansion#Broad based
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue189.675.0%34.4%
Total Income196.273.7%33.0%
Expenditure182.0510.3%7.5%
PBT16.99375.9%188.6%
Net Profit11.91441.4%185.0%
OPM9.63%5.42pp20.32pp
NPM6.07%4.99pp15.57pp
EPS1.90400.0%16.3%
View full financials

Pharma/biotech: adjusted net profit swung from a ₹14.01 Cr loss to a genuine ~₹9.1 Cr underlying profit on 34.4% revenue growth, driven by a real Vaccines-segment turnaround (not the offsetting one-off deferred-consideration gains), which caps it at good rather than very_good given the still-early recovery and flat Formulations segment.

Q2 FY-2027 RESULTS · PANACEABIO

Panacea Biotec swings to ₹11.9 Cr consolidated PAT in Q2 FY27, reversing year-ago loss

revenue +34.4% · margins expanding

14 Nov 2026 · 3 min read
Revenue

₹189.67 Cr

+34.4% YoY

PAT (consolidated)

₹11.91 Cr

Net margin

6.07%

+15.6pp YoY

EPS

₹1.9

Panacea Biotec's consolidated business turned profitable in Q2 FY27, posting a net profit of ₹11.91 Cr against a loss of ₹14.01 Cr in Q2 FY26, as consolidated revenue from operations grew 34.4% YoY to ₹189.67 Cr from ₹141.13 Cr. Net profit margin swung from -9.50% a year ago to +6.07% this quarter, continuing the gradual recovery seen in Q1 FY27 (NPM 1.08%, PAT ₹2.20 Cr) — QoQ profit growth looks dramatic at over 400%, but that is flattered by timing of a one-off item: Q1's ₹2.74 Cr exceptional gain was large enough relative to its thin reported profit that the underlying (ex-exceptional) business was roughly breakeven to slightly loss-making in Q1, whereas this quarter's underlying profit, net of its own ₹2.77 Cr exceptional gain, came in at a genuine ~₹9.1 Cr. Segment data shows the Vaccines business driving the turnaround, with segment PBT of ₹16.85 Cr versus a ₹16.57 Cr loss a year ago, while Formulations stayed roughly breakeven (₹0.14 Cr PBT vs a ₹2.60 Cr loss YoY). Sequentially, revenue dipped 4.96% from ₹199.57 Cr in Q1 FY27, a normal quarter-to-quarter fluctuation rather than a signal, with the YoY turnaround the primary story.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹189.67 Cr-5%+34.4%
Expenses₹182.05 Cr-10.3%+7.5%
PAT₹11.91 Cr+441.4%—
Net margin6.07%+5pp+15.6pp
EPS₹1.9+400%-16.3%

The exceptional income booked both this quarter and a year ago stems from the same source — deferred consideration on the 2022 sale of PBPL's domestic pharmaceutical formulation brands — and the two are similar enough in size (₹2.77 Cr now vs ₹2.70 Cr then) that they largely cancel out in the YoY comparison rather than distorting it; ₹4.68 Cr of that deferred consideration is still to be recognised in future quarters. Standalone results, which are secondary to consolidated, tell a consistent but slightly stronger story: standalone PAT of ₹10.75 Cr versus a ₹15.64 Cr loss YoY, on revenue growth of 39.5% YoY versus the consolidated 34.4% — the gap reflects the subsidiary layer (Panacea Biotec Pharma and overseas units) growing slower than the parent, but both bases agree on the direction: a genuine profit turnaround, not an accounting artifact.

₹
293.86327.17360.48393.78427.09354.408-1109-0209-2510-2111-1211-13
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹354.4, down 2.3% over the past month of trading.

₹ Cr
-17.12-6.414.3115.02-1.99Q4 FY25rev ₹133 Cr3.96Q1 FY26rev ₹167 Cr-14.01Q2 FY26rev ₹141 Cr3.89Q3 FY26rev ₹165 Cr2.2Q1 FY27rev ₹200 Cr11.91Q2 FY27rev ₹190 Cr
Quarterly consolidated PAT, ₹ Crore

For context: this is the highest quarterly PAT in the last 6 quarters on our records.

There is no management guidance or prior concall commentary on record to grade this print against, and no analyst consensus or brokerage preview for this specific quarter turned up in a web search, so vs-street and vs-guidance verdicts are both unknown rather than assumed. The quarter's corporate developments — a ₹4.32 Cr income-tax penalty demand (Sep 29, 2026) and a separate ₹9.82 Cr tax penalty demand (Sep 26, 2026) — are not reflected as exceptional items in this result and represent a separate, as-yet-unresolved tax exposure to track. The auditors flag a standalone-level going-concern note given negative standalone retained earnings of ₹205.10 Cr, but management's own framing (new vaccine capacity, higher long-term institutional orders) and the Group's positive retained earnings position support continuing on a going-concern basis for now — that framing is corroborated, not contradicted, by this quarter's operating turnaround.

  • W1

    Whether Vaccines segment profitability (PBT ₹16.85 Cr this quarter, from a ₹16.57 Cr loss a year ago) holds up, given management's cited higher long-term institutional vaccine orders

  • W2

    Recognition of the remaining ₹4.68 Cr deferred consideration from the PBPL brand sale in coming quarters, which has been a recurring source of exceptional income

  • W3

    Outcome/provisioning of the ₹4.32 Cr and ₹9.82 Cr tax penalty demands received in September 2026

Informational and educational content only. Not investment advice.